Non-Small Cell Lung Carcinoma TNM clinical staging | Squamous Cell Non-Small Cell Lung Carcinoma Excluded
Item
stage iiib and iv nsclc, excluded squamous cell nsclc
boolean
C0007131 (UMLS CUI [1,1])
C3258246 (UMLS CUI [1,2])
C0221910 (UMLS CUI [2,1])
C0007131 (UMLS CUI [2,2])
C0332196 (UMLS CUI [2,3])
Age
Item
age ≥ 65 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog 0-2
boolean
C1520224 (UMLS CUI [1])
Non-small cell carcinoma Small Cell Carcinoma Mixed | Adenosquamous carcinoma Component Squamous Mixed
Item
mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component
boolean
C1266002 (UMLS CUI [1,1])
C0262584 (UMLS CUI [1,2])
C0205430 (UMLS CUI [1,3])
C0206623 (UMLS CUI [2,1])
C1705248 (UMLS CUI [2,2])
C1182670 (UMLS CUI [2,3])
C0205430 (UMLS CUI [2,4])
Hemoptysis
Item
history of haemoptysis
boolean
C0019079 (UMLS CUI [1])
Tumor Invasion Blood Vessels Major Imaging
Item
evidence of tumour invading major blood vessels on imaging
boolean
C1269955 (UMLS CUI [1,1])
C0005847 (UMLS CUI [1,2])
C0205164 (UMLS CUI [1,3])
C0011923 (UMLS CUI [1,4])
Therapeutic radiology procedure
Item
radiotherapy within 28 days prior to enrolment
boolean
C1522449 (UMLS CUI [1])
Unable to discontinue Aspirin | Unable to discontinue Non-Steroidal Anti-Inflammatory Agents | Exception Aspirin U/day Time Period | Exception Piroxicam Time Period
Item
patients who are unable to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for long-acting agents, such as piroxicam)
boolean
C1548265 (UMLS CUI [1,1])
C0004057 (UMLS CUI [1,2])
C1548265 (UMLS CUI [2,1])
C0003211 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0004057 (UMLS CUI [3,2])
C0456683 (UMLS CUI [3,3])
C1948053 (UMLS CUI [3,4])
C1705847 (UMLS CUI [4,1])
C0031990 (UMLS CUI [4,2])
C1948053 (UMLS CUI [4,3])
Oral anticoagulants Dosage Full | Anticoagulants Parenteral | Fibrinolytic Agents | Anticoagulants Prophylactic allowed
Item
current or recent (within 10 days of first dose of bevacizumab) use of full-dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes. prophylactic use of anticoagulants is allowed
boolean
C0354604 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0443225 (UMLS CUI [1,3])
C0003280 (UMLS CUI [2,1])
C1518896 (UMLS CUI [2,2])
C0016018 (UMLS CUI [3])
C0003280 (UMLS CUI [4,1])
C0199176 (UMLS CUI [4,2])
C0683607 (UMLS CUI [4,3])
Cardiovascular Disease | Cerebrovascular accident | Myocardial Infarction | Angina, Unstable | Congestive heart failure New York Heart Association Classification | Cardiac Arrhythmia Serious Requirement Pharmaceutical Preparations | Cardiac Arrhythmia Serious Interferes with Study Protocol | Cardiac Arrhythmia Serious Uncontrolled
Item
clinically significant (i.e. active) cardiovascular disease for example cva (≤6 months before enrolment), myocardial infarction (≤6 months before enrolment), unstable angina, chf nyha class ≥ii, serious cardiac arrhythmia requiring medication during the study and might interfere with regularity of the study treatment, or not controlled by medication
boolean
C0007222 (UMLS CUI [1])
C0038454 (UMLS CUI [2])
C0027051 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0018802 (UMLS CUI [5,1])
C1275491 (UMLS CUI [5,2])
C0003811 (UMLS CUI [6,1])
C0205404 (UMLS CUI [6,2])
C1514873 (UMLS CUI [6,3])
C0013227 (UMLS CUI [6,4])
C0003811 (UMLS CUI [7,1])
C0205404 (UMLS CUI [7,2])
C0521102 (UMLS CUI [7,3])
C2348563 (UMLS CUI [7,4])
C0003811 (UMLS CUI [8,1])
C0205404 (UMLS CUI [8,2])
C0205318 (UMLS CUI [8,3])
Wound, non-healed | Peptic Ulcer | Fracture
Item
non-healing wound, active peptic ulcer or bone fracture
boolean
C0750433 (UMLS CUI [1])
C0030920 (UMLS CUI [2])
C0016658 (UMLS CUI [3])
Abdominal fistula | Gastrointestinal perforation | Abdominal Abscess
Item
history of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment
boolean
C1879311 (UMLS CUI [1])
C0151664 (UMLS CUI [2])
C0243001 (UMLS CUI [3])